L. Collette

发表

Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial

M. Piérart, MJ van den Bent, D. Áfra, 2005, The Lancet.

Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911)

L. Collette, K. Haustermans, M. Bolla, 2012, The Lancet.

Impact of pathology review of stage and margin status of radical prostatectomy specimens (EORTC trial 22911)

L. Collette, F. Schröder, M. Bolla, 2006, Virchows Archiv.

Multicentre analysis of oncological and survival outcomes following anastomotic leakage after rectal cancer surgery

H. Putter, L. Collette, L. Påhlman, 2009, The British journal of surgery.

A Systematic Review and Recommendation for Reporting of Surrogate Endpoint Evaluation Using Meta-analyses

L. Collette, M. Sydes, M. Regan, 2019, JNCI cancer spectrum.

Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer.

P. Kantoff, L. Collette, M. Sydes, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guérin.

L. Collette, T. D. de Reijke, R. Sylvester, 2016, European urology.

Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3.

R. Greil, R. Labianca, L. Collette, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Internal Mammary and Medial Supraclavicular Irradiation in Breast Cancer.

Laurence Collette, Rodrigo Arriagada, Erik Van Limbergen, 2015, The New England journal of medicine.

Impact of a Higher Radiation Dose on Local Control and Survival in Breast-Conserving Therapy of Early Breast Cancer: 10-Year Results of the Randomized Boost Versus No Boost EORTC 22881-10882 Trial

Laurence Collette, Jos J. Jager, Harry Bartelink, 2007 .

Clinical trial designs for predictive marker validation in cancer treatment trials.

Daniel J Sargent, Laurence Collette, L. Collette, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Defining dose-limiting toxicity for phase 1 trials of molecularly targeted agents: results of a DLT-TARGETT international survey.

Percy Ivy, Xavier Paoletti, Laurence Collette, 2014, European journal of cancer.

Randomized phase III study comparing paclitaxel-bleomycin, etoposide, and cisplatin (BEP) to standard BEP in intermediate-prognosis germ-cell cancer: intergroup study EORTC 30983.

L. Collette, P. Albers, M. D. De Santis, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data

Caroline Domerg, Stefan Michiels, Herbert Pang, 2013, The Lancet. Oncology.

Quality assurance of the EORTC 22043-30041 trial in post-operative radiotherapy in prostate cancer: results of the Dummy Run procedure.

Michel Bolla, Akos Gulyban, Laurence Collette, 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Profile of European radiotherapy departments contributing to the EORTC Radiation Oncology Group (ROG) in the 21st century.

L. Collette, G. Tienhoven, A. Monti, 2008, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial.

Jacques Bernier, Michel Bolla, Laurence Collette, 1997, Radiotherapy and Oncology.

Repeatability and reproducibility of ADC measurements: a prospective multicenter whole-body-MRI study

J. Vandemeulebroucke, L. Collette, N. Michoux, 2021, European Radiology.

Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial

Jacques Bernier, Michel Bolla, Laurence Collette, 2002, The Lancet.

Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. European Organization for Research and Treatment of Cancer.

L. Collette, R. Sylvester, R. de Wit, 1998, British Journal of Cancer.

Impact of the treating institution on survival of patients with "poor-prognosis" metastatic nonseminoma. European Organization for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group and the Medical Research Council Testicular Cancer Working Party.

L. Collette, S. Fosså, R. Sylvester, 1999, Journal of the National Cancer Institute.

Selection bias is not a good reason for advising more than 5 years of adjuvant hormonal therapy for all patients with locally advanced prostate cancer treated with radiotherapy.

L. Collette, U. Studer, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Timing to achieve the highest rate of pCR after preoperative radiochemotherapy in rectal cancer: a pooled analysis of 3085 patients from 7 randomized trials.

L. Collette, J. van Soest, A. Dekker, 2020, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

What is the clinical benefit of preoperative chemoradiotherapy with 5FU/leucovorin for T3-4 rectal cancer in a pooled analysis of EORTC 22921 and FFCD 9203 trials: surrogacy in question?

L. Collette, G. Calais, T. Conroy, 2012, European journal of cancer.

Preoperative radiation (Preop RT) in rectal cancer: Effect and timing of additional chemotherapy (CT) 5-year results of the EORTC 22921 trial

L. Collette, G. Calais, J. Bosset, 2005 .

A Risk Score for Predicting Death in Chagas' Heart Disease

L. Collette, J. Bosset, P. Maingon, 2006 .

Cumulative Toxicity in Targeted Therapies: What to Expect at the Recommended Phase II Dose.

L. Collette, X. Paoletti, Maria-Athina Altzerinakou, 2019, Journal of the National Cancer Institute.

Concomitant and adjuvant androgen deprivation (ADT) with external beam irradiation (RT) for locally advanced prostate cancer: 6 months versus 3 years ADT--Results of the randomized EORTC Phase III trial 22961

M. Piérart, L. Collette, M. Bolla, 2007 .

Trial design on prophylaxis and treatment of brain metastases: lessons learned from the EORTC Brain Metastases Strategic Meeting 2012.

D. Schadendorf, L. Collette, J. Reijneveld, 2012, European journal of cancer.

EORTC prostate cancer trials: what have we learnt?

L. Collette, T. D. de Reijke, 2002, Critical reviews in oncology/hematology.

Why phase III trials of maximal androgen blockade versus castration in M1 prostate cancer rarely show statistically significant differences *

L. Collette, F. Schröder, R. Sylvester, 2001, The Prostate.

Phase III Trial of Satraplatin, an Oral Platinum plus Prednisone vs. Prednisone alone in Patients with Hormone-Refractory Prostate Cancer

L. Collette, C. Sternberg, D. Lebwohl, 2005, Oncology.

An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: diagnosis and therapeutic outcome. EORTC Invasive Fungal Infections Cooperative Group.

R Sylvester, L Collette, L. Collette, 1998, The Journal of infection.

Quality control of radical prostatectomy: a feasibility study.

L. Collette, H. V. Van Poppel, D. Newling, 2001, European journal of cancer.

Treatment of prostate cancer with goserelin and radiotherapy - Reply

L. Collette, M. Bolla, 1997 .

Adjuvant postoperative high-dose radiotherapy for atypical and malignant meningioma: A phase-II parallel non-randomized and observation study (EORTC 22042-26042).

L. Collette, Yan Liu, A. Pica, 2018, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Prognostic Factors for Local Control in Breast Cancer After Long-term Follow-up in the EORTC Boost vs No Boost Trial: A Randomized Clinical Trial

E. van Limbergen, H. Bartelink, J. Horiot, 2017, JAMA oncology.

The abdominoperineal resection itself is associated with an adverse outcome: the European experience based on a pooled analysis of five European randomised clinical trials on rectal cancer.

H. Putter, L. Collette, L. Påhlman, 2009, European journal of cancer.

WHAT HAS BEEN LEARNED FROM META‐ANALYSES OF NEOADJUVANT AND ADJUVANT CHEMOTHERAPY IN BLADDER CANCER?

L. Collette, C. Sternberg, 2006, BJU international.

IN REPLY: Morgan and Robertson underline our remarkable

H. Bartelink, J. Horiot, L. Collette, 2007 .

Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation.

I. Barillot, H. Bartelink, J. Horiot, 2001, The New England journal of medicine.

Comment on the “TrialsTracker: Automated ongoing monitoring of failure to share clinical trial results by all major companies and research institutions”

L. Collette, J. Bogaerts, C. Coens, 2017 .

An analysis of preoperative chemoradiotherapy with 5FU/leucovorin for T3-4 rectal cancer on survival in a pooled analysis of EORTC 22921 and FFCD 9203 trials: Surrogacy in question?

L. Collette, G. Calais, T. Conroy, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of the COVID-19 crisis on imaging in oncological trials

L. de Geus-Oei, L. Collette, L. Bidaut, 2020, European Journal of Nuclear Medicine and Molecular Imaging.

Surgery vs surgery and chemotherapy for colorectal liver metastases – Authors' reply

L. Collette, B. Nordlinger, H. Sorbye, 2008, The Lancet.

Chapter 9 The association between diverting stomas and symptomatic anastomotic leakage after low anterior resection for rectal cancer

H. Putter, L. Collette, L. Påhlman, 2009 .

European Organisation of Research and Treatment of Cancer (EORTC) Gastrointestinal Group: Workshop on the role of metabolic imaging in the neoadjuvant treatment of gastrointestinal cancer.

L. Collette, D. Aust, E. Van Cutsem, 2008, European journal of cancer.

Comparison of Local Control of Brain Metastases With Stereotactic Radiosurgery vs Surgical Resection: A Secondary Analysis of a Randomized Clinical Trial

L. Collette, R. Soffietti, B. Alexander, 2019, JAMA oncology.

Biopsy diagnosis of intraductal carcinoma is prognostic in intermediate and high risk prostate cancer patients treated by radiotherapy.

T. H. van der Kwast, L. Collette, R. Mirimanoff, 2012, European journal of cancer.

Tissue polypeptide-specific antigen (TPS) determinations before and during intermittent maximal androgen blockade in patients with metastatic prostatic carcinoma.

L. Collette, T. D. de Reijke, U. Studer, 2003, European urology.

Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19805 patients, on behalf of MACH-NC group.

B. Jeremic, L. Collette, J. Pignon, 2021, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Impact of acute kidney injury on anticancer treatment dosage and long-term outcomes: a pooled analysis of European Organisation for Research and Treatment of Cancer trials.

L. Collette, A. Neven, B. Sprangers, 2020, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Does the addition of chemotherapy (CT) to preoperative radiotherapy (preopRT) increase the pathological response in patients with resected rectal cancer : Report of the 22921 EORTC phase III trial.

L. Collette, G. Calais, J. Bosset, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Results of the phase II EORTC 22971 trial evaluating combined accelerated external radiation and chemotherapy with 5FU and cisplatin in patients with muscle invasive transitional cell carcinoma of the bladder

M. Piérart, L. Collette, M. Bolla, 2008, Acta oncologica.

Cytoreductive nephrectomy and exposure to sunitinib – a post hoc analysis of the Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer (SURTIME) trial

L. Collette, B. Tombal, C. Blank, 2022 .

Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours.

L. Collette, J. Witjes, C. Sternberg, 2006, European journal of cancer.

Radiation dose homogeneity in an EORTC multicenter trial on breast irradiation.

H. Bartelink, J. Horiot, M. Piérart, 1999, Acta oncologica.

Impact of a boost dose of 16 GY on the local control and cosmesis in patients with early breast cancer: The EORTC ‘boost versus no boost’ trial

J. Peterse, H. Bartelink, J. Horiot, 2000 .

Quality of surgery in T3-4 rectal cancer: involvement of circumferential resection margin not influenced by preoperative treatment. Results from EORTC 22921 trial

L. Collette, G. Calais, C. Marijnen, 2009 .

Quality of surgery in T3-4 rectal cancer: involvement of circumferential resection margin not influenced by preoperative treatment. Results from EORTC trial 22921.

L. Collette, G. Calais, C. Marijnen, 2007, European Journal of Cancer.

Estimating Number of Events from the Kaplan–Meier Curve for Incorporation in a Literature‐Based Meta‐Analysis: What You Don't See You Can't Get!

L. Collette, J. Pignon, L. Duchateau, 2000, Biometrics.

Overall Survival in Men With Bone Metastases From Castration-Resistant Prostate Cancer Treated With Bone-Targeting Radioisotopes: A Meta-analysis of Individual Patient Data From Randomized Clinical Trials.

L. Collette, C. Parker, B. Erikstein, 2019, JAMA oncology.

Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation.

L. Collette, A. Dekker, M. Scorsetti, 2020, The Lancet. Oncology.

Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891.

L. Collette, T. D. de Reijke, U. Studer, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911)

M. Piérart, L. Collette, K. Haustermans, 2005, The Lancet.

How to Interpret Numeric Results in Publications

L. Collette, 2017 .

The EORTC Genito-Urinary Cancers Group: 35 years of achievements and future strategy

L. Collette, R. Sylvester, B. Tombal, 2012 .

Does post-operative radiotherapy (P-RXT) after radical prostatectomy (Px) improve progression-free survival (PFS) in pT3N0 prostate cancer (PC)? (EORTC 22911).

L. Collette, T. D. de Reijke, P. Rigatti, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

ADJUVANT RADIOTHERAPY AFTER RADICAL PROSTATECTOMY IN PATIENTS WITH PATHOLOGICALLY HIGH RISK PROSTATE CANCER

L. Collette, K. Haustermans, T. Gasser, 2011 .

227 ADJUVANT RADIOTHERAPY AFTER RADICAL PROSTATECTOMY IN PATIENTS WITH PATHOLOGICALLY HIGH RISK PROSTATE CANCER: 10-YEAR FOLLOW-UP RESULTS

L. Collette, K. Haustermans, T. Gasser, 2011 .

Quality Assurance in the EORTC Randomized Trial 22922/10925 Investigating the Role of Irradiation of the Internal Mammary and Medial Supraclavicular Lymph Node Chain Works

P. Lambin, L. Collette, G. Tienhoven, 2006, Strahlentherapie und Onkologie.

Toxicity at three years with and without irradiation of the internal mammary and medial supraclavicular lymph node chain in stage I to III breast cancer (EORTC trial 22922/10925)

H. Bartelink, M. Piérart, L. Collette, 2010, Acta oncologica.

Radical prostatectomy for locally advanced prostate cancer: results of a feasibility study (EORTC 30001).

L. Collette, R. Montironi, L. D. Pozzo, 2006, European journal of cancer.

Are prostate-specific antigen changes valid surrogates for survival in hormone-refractory prostate cancer? A meta-analysis is needed!

L. Collette, M. Buyse, T. Burzykowski, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Oncology clinical trials

P. Müller, T. Lai, G. Rosner, 2013 .

Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial.

H. Bartelink, J. Horiot, J. Jager, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Re: Design and endpoints of clinical trials in patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.

L. Collette, 2008, European urology.

Histologic and autoradiographic study of the in vitro effects of FGF-2 and FSH on isolated bovine preantral follicles: preliminary investigation.

L. Collette, F. Dessy, A. Massip, 1996, Theriogenology.

[Breast cancer in the early stage].

R. J. Jones, M. Espié, G. Giaccone, 2012, Gan no rinsho. Japan journal of cancer clinics.

Decreased fracture rate by mandating bone-protecting agents in the EORTC 1333/PEACE III trial comparing enzalutamide and Ra223 versus enzalutamide alone: An interim safety analysis.

L. Collette, F. Saad, B. Tombal, 2019, Journal of Clinical Oncology.

Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19805 patients, on behalf of MACH-NC group.

B. Jeremic, L. Collette, J. Pignon, 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis.

L. Collette, R. Sylvester, M. Boogaerts, 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

ESMO-MCBS: setting the record straight - Authors' reply.

L. Collette, R. Audisio, C. Grau, 2019, The Lancet. Oncology.

Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents--dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation fo

L. Collette, D. Lacombe, L. Seymour, 2014, European journal of cancer.

Final results of the EORTC Intergroup randomized phase III study 40983 [EPOC] evaluating the benefit of peri-operative FOLFOX4 chemotherapy for patients with potentially resectable colorectal cancer liver metastases

L. Collette, P. Schlag, B. Nordlinger, 2007 .

Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a Randomized Medical Research Council/European Organization for Research and Treatment of Cancer study.

R Sylvester, L Collette, L. Collette, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom.

L. Collette, S. Fosså, S. Kaye, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Quality of life in good prognosis patients with metastatic germ cell cancer: a prospective study of the European Organization for Research and Treatment of Cancer Genitourinary Group/Medical Research Council Testicular Cancer Study Group (30941/TE20).

L. Collette, S. Fosså, N. Aaronson, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Serum Alpha-Fetoprotein Surge After the Initiation of Chemotherapy for Non-Seminomatous Testicular Cancer Has an Adverse Prognostic Significance

L. Collette, A. Oosterom, R. Sylvester, 1999 .

Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group.

L. Collette, R. Sylvester, S. Kaye, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Immediate versus deferred cytoreductive nephrectomy (CN) in patients with synchronous metastatic renal cell carcinoma (mRCC) receiving sunitinib (EORTC 30073 SURTIME)

L. Collette, B. Tombal, R. Velthoven, 2017 .

A randomized phase III study comparing paclitaxel-BEP (T-BEP) to standard BEP in patients with in intermediate prognosis germ cell cancer (GCC): An intergroup study of EORTC, German TCSG/AUO, MRC, and Spanish GCC group (EORTC 30983).

L. Collette, P. Albers, J. Witjes, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Seven year update of an EORTC phase III trial of high dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumors

L. Collette, S. Fosså, C. Sternberg, 2005 .

Whole brain radiotherapy after stereotactic radiosurgery or surgical resection among patients with one to three brain metastases and favorable prognoses: a secondary analysis of EORTC 22952-26001

L. Collette, R. Soffietti, B. Alexander, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

EORTC GENITO-URINARY CANCER COOPERATIVE GROUP EORTC PROTOCOL 30983 RANDOMIZED PHASE II/III STUDY OF TAXOL-BEP VERSUS BEP IN PATIENTS WITH INTERMEDIATE PROGNOSIS GERM CELL CANCER

L. Collette, D. Curran, R. Wit, 1998 .

The European Organization for Research and Treatment for Cancer (EORTC) strategy for quality assurance in surgical clinical research: Assessment of the past and moving towards the future.

L. Collette, D. Lacombe, E. Tanis, 2016, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Intermittent maximal androgen blockade in patients with metastatic prostate cancer: an EORTC feasibility study.

L. Collette, T. D. de Reijke, U. Studer, 2003, European urology.

BPA uptake does not correlate with LAT1 and Ki67 expressions in tumor samples (results of EORTC trial 11001).

L. Collette, L. Brualla, A. Wittig, 2011, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

Prostate specific antigen: a prognostic marker of survival in good prognosis metastatic prostate cancer? (EORTC 30892).

L. Collette, T. D. de Reijke, F. Schröder, 2003, European urology.

8704 Adjuvant whole brain radiotherapy versus observation after radiosurgery or surgical resection of 1–3 cerebral metastases results of the EORTC 22952–26001 study

L. Collette, R. Soffietti, F. Fauchon, 2009 .

Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin.

M. Piérart, L. Collette, R. Mirimanoff, 1997, The New England journal of medicine.

Association of Gleason Grade With Androgen Deprivation Therapy Duration and Survival Outcomes: A Systematic Review and Patient-Level Meta-analysis

A. Kishan, L. Collette, T. D. de Reijke, 2019, JAMA oncology.

Adjuvant hormone therapy in locally advanced and localized prostate cancer: three EORTC trials.

L. Collette, T. D. de Reijke, M. Bolla, 2002, Frontiers of radiation therapy and oncology.

Serum alpha-fetoprotein surge after the initiation of chemotherapy for non-seminomatous testicular cancer has an adverse prognostic significance.

L. Collette, R. Sylvester, A. V. van Oosterom, 1998, British Journal of Cancer.

[Hyperfractionated and accelerated radiotherapy in head and neck cancers: results of the EORTC trials and impact on clinical practice].

J. Horiot, M. Piérart, M. van Glabbeke, 1996, Bulletin du cancer. Radiotherapie : journal de la Societe francaise du cancer : organe de la societe francaise de radiotherapie oncologique.

Do results of the EORTC dummy run predict quality of radiotherapy delivered within multicentre clinical trials?

L. Collette, A. Fairchild, C. Hurkmans, 2012, European journal of cancer.

A study from the EORTC new drug development group: open label phase II study of sabarubicin (MEN-10755) in patients with progressive hormone refractory prostate cancer.

L. Collette, D. Lacombe, W. Fiedler, 2006, European journal of cancer.

Strontium89 Chloride versus Palliative Local Field Radiotherapy in Patients with Hormonal Escaped Prostate Cancer: A Phase III Study of the European Organisation for Research and Treatment of Cancer Genitourinary Group

L. Collette, M. Debois, S. Horenblas, 2003 .

Dose-Finding Methods: Moving Away from the 3 + 3 to Include Richer Outcomes

L. Collette, D. Drubay, X. Paoletti, 2017, Clinical Cancer Research.

Title: Dose-finding methods: Moving away from the 3+3 to include richer outcomes Running Title: Dose finding methods needs richer outcomes

L. Collette, D. Drubay, X. Paoletti, 2017 .

Adjuvant chemotherapy for rectal cancer--authors' reply.

L. Collette, J. Bosset, 2014, The Lancet. Oncology.

Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial.

E. van Limbergen, H. Bartelink, J. Horiot, 2015, The Lancet. Oncology.

Is laryngeal preservation (LP) with induction chemotherapy (ICT) safe in the treatment of hypopharyngeal SCC? Final results of the phase III EORTC 24891 trial.

L. Collette, J. Bernier, G. Andry, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group.

L. Collette, T. Sahmoud, B. Luboinski, 1996, Journal of the National Cancer Institute.

Final analysis demonstrating the equivalence of 3 BEP vs 4 cycles and the 5 day schedule vs 3 days per cycle in good prognosis germ cell cancer. An EORTC / MRC Phase III Study

L. Collette, P. Wilkinson, G. Mead, 2000 .

Quality of Life in Patients with Good Prognosis Metastatic Germ Cell Tumours: Comparison of Four Chemotherapy Schedules (EORTC 30941/MRC TE20)

L. Collette, S. Fosså, N. Aaronson, 2002 .

Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium

L. Collette, S. Culine, R. Huddart, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Predictive validity of NeoAdjuvant Rectal (NAR) Score and pathologic complete response (ypCR) for overall survival (OS) as surrogate endpoints in rectal cancer clinical trial.

L. Collette, N. Wolmark, J. Bosset, 2016 .

Strontium(89) chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer: a phase III study of the European Organisation for Research and Treatment of Cancer, Genitourinary Group.

L. Collette, T. D. de Reijke, M. Debois, 2003, European urology.

Duration of androgen suppression in the treatment of prostate cancer.

M. Piérart, L. Collette, T. D. de Reijke, 2009, The New England journal of medicine.

Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC).

B. Lebeau, L. Collette, C. Viscoli, 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891).

L. Collette, T. D. de Reijke, U. Studer, 2008, European urology.

Long-Term Follow-Up of an EORTC Randomized Prospective Trial Comparing Intravesical Bacille Calmette-Guerin-RIVM and Mitomycin C in Superficial Bladder Cancer

Richard Sylvester, Laurence Collette, J. A. Witjes, 1999 .

Reliability of clinical research on invasive fungal infections: a systematic review of the literature.

L. Collette, B. D. de Pauw, J. Donnelly, 2001, Medical mycology.

Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer: a consensus recommendation from the EORTC Imaging Group.

L. Collette, L. Bidaut, O. Hoekstra, 2018, The Lancet. Oncology.

Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial

Thomas Gruenberger, Laurence Collette, Peter M Schlag, 2008, The Lancet.

Is baseline quality of life useful for predicting survival with hormone-refractory prostate cancer? A pooled analysis of three studies of the European Organisation for Research and Treatment of Cancer Genitourinary Group.

L. Collette, S. Fosså, T. D. de Reijke, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies.

Laurence Collette, L. Collette, J. Witjes, 2002, European urology.

Long-term follow-up of an EORTC randomized prospective trial comparing intravesical bacille Calmette-Guérin-RIVM and mitomycin C in superficial bladder cancer. EORTC GU Group and the Dutch South East Cooperative Urological Group. European Organisation for Research and Treatment of Cancer Genito-Urin

L. Collette, J. Witjes, R. Sylvester, 1998, Urology.

Modulation of high-dose infusional fluorouracil by low-dose methotrexate in patients with advanced or metastatic colorectal cancer: final results of a randomized European Organization for Research and Treatment of Cancer Study.

L. Collette, J. De Grève, G. Blijham, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

f or R esearch a nd Treatm e nt o f

L. Collette, T. Sahmoud, H. Bleiberg, 1996 .

Expression of the androgen-regulated fusion gene TMPRSS2-ERG does not predict response to endocrine treatment in hormone-naïve, node-positive prostate cancer.

L. Collette, P. Verhagen, J. Trapman, 2010, European urology.

International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: recommendations of the SISAQOL Consortium.

Michael Koller, Corneel Coens, Andrew Bottomley, 2020, The Lancet. Oncology.

International evaluation of the psychometrics of health-related quality of life questionnaires for use among long-term survivors of testicular and prostate cancer

L. Collette, S. Fosså, N. Aaronson, 2017, Health and Quality of Life Outcomes.

O-0028 Adjuvant Folfox4 +/- Cetuximab in KRAS Wild-Type Patients with Resected Stage III Colon Cancer Results from the Petacc8 Intergroup Trial

L. Collette, P. Laurent-Puig, J. Tabernero, 2012 .

Predictors of the risk of fibrosis at 10 years after breast conserving therapy for early breast cancer: a study based on the EORTC Trial 22881-10882 'boost versus no boost'.

Michel Bolla, Laurence Collette, John Kurtz, 2008, European journal of cancer.

Patients at high risk of progression after radical prostatectomy: do they all benefit from immediate post-operative irradiation? (EORTC trial 22911).

M. Piérart, L. Collette, T. D. de Reijke, 2005, European journal of cancer.

Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials: a start in setting international standards.

L. Collette, M. Piccart, M. Taphoorn, 2016, The Lancet. Oncology.

Perioperative chemotherapy with FOLFOX 4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer ( EORTC Intergroup trial 40983 ) : a randomised controlled trial

R. Parks, L. Collette, P. Schlag, 2008 .

Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer Radiation Oncology Group.

M. Piérart, L. Collette, G. Calais, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prophylactic cranial irradiation in extensive small-cell lung cancer.

L. Collette, P. Postmus, C. Faivre-Finn, 2007, The New England journal of medicine.

Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results--EORTC 22921.

Laurence Collette, Gilles Calais, L. Collette, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chemotherapy with preoperative radiotherapy in rectal cancer.

Laurence Collette, Gilles Calais, L. Collette, 2006, The New England journal of medicine.

J. Horiot, M. Piérart, L. Collette, 1997, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc 99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer?

Laurence Collette, Jean-Pascal Machiels, François Jamar, 2012, European urology.

Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer.

L. Collette, D. Lacombe, C. Sternberg, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Acute toxicity of curative radiotherapy for intermediate- and high-risk localised prostate cancer in the EORTC trial 22991.

L Collette, O Matzinger, M Bolla, 2009, European journal of cancer.

Quality assurance in breast cancer: EORTC experiences in the phase III trial on irradiation of the internal mammary nodes.

H. Bartelink, M. Piérart, L. Collette, 2007, European journal of cancer.

Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium

L. Collette, R. Huddart, C. Bokemeyer, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.

L. Collette, R. Salazar, P. Laurent-Puig, 2014, The Lancet. Oncology.

The sex ratio of bovine embryos produced in vitro in serum-free oviduct cell-conditioned medium is not altered.

L. Collette, B. Grisart, F. Dessy, 1995, Theriogenology.

Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer

L. Collette, C. Sternberg, J. Schornagel, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Nomograms for predicting local recurrence, distant metastases, and overall survival for patients with locally advanced rectal cancer on the basis of European randomized clinical trials.

Vincenzo Valentini, Philippe Lambin, Laurence Collette, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Can patient-, treatment- and pathology-related characteristics explain the high local recurrence rate following breast-conserving therapy in young patients?

L Collette, A Fourquet, W Van den Bogaert, 2003, European journal of cancer.

Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial.

L. Collette, S. Fosså, P. Albers, 2015, The Lancet. Oncology.

External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study.

C. L. Cutajar, L. Collette, R. Mirimanoff, 2010, The Lancet. Oncology.

Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation.

D. Berry, A. D'Amico, P. Kantoff, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prostate-specific antigen (PSA) as a surrogate end point for survival in prostate cancer clinical trials.

L. Collette, 2008, European urology.

Differences in time to disease progression do not predict for cancer-specific survival in patients receiving immediate or deferred androgen-deprivation therapy for prostate cancer: final results of EORTC randomized trial 30891 with 12 years of follow-up.

L. Collette, T. D. de Reijke, U. Studer, 2014, European urology.

Short‐ vs long‐term androgen suppression plus external beam radiation therapy and survival in men of advanced age with node‐negative high‐risk adenocarcinoma of the prostate

A. D'Amico, Ming-Hui Chen, L. Collette, 2007, Cancer.

A European Organisation for Research and Treatment of Cancer phase III trial of adjuvant whole-brain radiotherapy versus observation in patients with one to three brain metastases from solid tumors after surgical resection or radiosurgery: quality-of-life results.

L. Collette, A. Bottomley, R. Soffietti, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study.

L. Collette, R. Soffietti, F. Fauchon, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Statistical analysis of patient-reported outcome data in randomised controlled trials of locally advanced and metastatic breast cancer: a systematic review.

L. Collette, M. Piccart, J. Reijneveld, 2018, The Lancet. Oncology.

The influence of patient, tumor and treatment factors on the cosmetic results after breast-conserving therapy in the EORTC 'boost vs. no boost' trial. EORTC Radiotherapy and Breast Cancer Cooperative Groups.

L Collette, A Fourquet, E Van Limbergen, 2000, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Validation of the methods of cosmetic assessment after breast-conserving therapy in the EORTC "boost versus no boost" trial. EORTC Radiotherapy and Breast Cancer Cooperative Groups. European Organization for Research and Treatment of Cancer.

J C Horiot, L Collette, E Van Limbergen, 1999, International journal of radiation oncology, biology, physics.

Laryngeal preservation with induction chemotherapy for hypopharyngeal squamous cell carcinoma: 10-year results of EORTC trial 24891.

L. Collette, J. Langendijk, G. Andry, 2012, Annals of Oncology.

Statistical methodology of phase III cancer clinical trials: advances and future perspectives.

M. van Glabbeke, L. Collette, T. Gorlia, 2002, European journal of cancer.

Prostate cancer treated by anti-androgens: is sexual function preserved?

L. Collette, T. Reijke, P. Whelan, 2000, British Journal of Cancer.

Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial

R.C.E. van Velthoven, L. Collette, B. Tombal, 2019, JAMA oncology.

Correcting the bias of the net benefit estimator due to right‐censored observations

D. Maucort-Boulch, L. Collette, M. Buyse, 2021, Biometrical journal. Biometrische Zeitschrift.

Impact of Primary Tumor Location on Survival from the European Organization for the Research and Treatment of Cancer Advanced Urothelial Cancer Studies

L. Collette, S. Shariat, B. Tombal, 2017, The Journal of urology.

Recruiting long-term survivors of European Organisation for Research and Treatment of Cancer phase III clinical trials into quality of life studies: challenges and opportunities.

L. Collette, S. Fosså, N. Aaronson, 2014, European journal of cancer.

Protocol of the Definition for the Assessment of Time-to-event Endpoints in CANcer trials (DATECAN) project: formal consensus method for the development of guidelines for standardised time-to-event endpoints' definitions in cancer clinical trials.

Thomas Filleron, Murielle Mauer, Simone Mathoulin-Pélissier, 2013, European journal of cancer.

Proportional odds assumption for modeling longitudinal ordinal multiple toxicity outcomes in dose finding studies of targeted agents: A pooled analysis of 54 studies

L. Collette, D. Drubay, X. Paoletti, 2020, Contemporary clinical trials communications.

The case against censoring of progression-free survival in cancer clinical trials – A pandemic shutdown as an illustration

L. Collette, E. Saad, T. Burzykowski, 2021, BMC Medical Research Methodology.

Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 ‘CREATE’

J. Blay, L. Collette, R. Sciot, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 'CREATE'.

L. Collette, R. Sciot, J. Šufliarský, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Predictive Factors for the Benefit of Perioperative FOLFOX for Resectable Liver Metastasis in Colorectal Cancer Patients (EORTC Intergroup Trial 40983)

R. Parks, L. Collette, W. Scheithauer, 2012, Annals of surgery.

Tailored follow-up for early breast cancer patients: a prognostic index that predicts locoregional recurrence.

H. Putter, H. Bartelink, L. Collette, 2010, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Prophylactic cranial irradiation in extensive disease small-cell lung cancer: short-term health-related quality of life and patient reported symptoms: results of an international Phase III randomized controlled trial by the EORTC Radiation Oncology and Lung Cancer Groups.

Andrew Bottomley, Suresh Senan, Corinne Faivre-Finn, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

50 years of the EORTC and the central role of the EORTC Headquarters

L. Collette, D. Lacombe, A. Bottomley, 2012 .

Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II study.

L. Collette, V. Budach, K. Haustermans, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 'CREATE'.

L. Collette, R. Sciot, J. Šufliarský, 2019 .

A multinational, multi-tumour basket study in very rare cancer types: The European Organization for Research and Treatment of Cancer phase II 90101 'CREATE' trial.

L. Collette, J. Steuve, P. Schöffski, 2019, European journal of cancer.

One‐step TNM staging of high‐risk prostate cancer using magnetic resonance imaging (MRI): Toward an upfront simplified “all‐in‐one” imaging approach?

Laurence Collette, François Jamar, Nicolas Michoux, 2014, The Prostate.

Adjuvant chemotherapy after preoperative (chemo)radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data.

H. Putter, L. Collette, C. V. D. van de Velde, 2015, The Lancet. Oncology.

Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer.

L. Collette, T. Conroy, M. Namer, 1997, European journal of cancer.

The impact of isolated local recurrence on long-term outcome in early-breast cancer patients after breast-conserving therapy.

H. Bartelink, L. Collette, S. Litière, 2021, European journal of cancer.

Towards an evidence-informed value scale for surgical and radiation oncology: a multi-stakeholder perspective.

L. Collette, R. Audisio, C. Grau, 2019, The Lancet. Oncology.

Whole body MRI in spondyloarthritis (SpA): Preliminary results suggest that DWI outperforms STIR for lesion detection

L. Collette, N. Michoux, F. Lecouvet, 2018, European Radiology.

Effect of age and radiation dose on local control after breast conserving treatment: EORTC trial 22881-10882.

I. Barillot, H. Bartelink, J. Horiot, 2007, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of 1-3 cerebral metastases: Results of the EORTC 22952-26001 study.

L. Collette, R. Soffietti, F. Fauchon, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Controlled Trials

S. Groshen, L. Collette, M. Parmar, 2021, European urology.

Short Androgen Suppression and Radiation Dose Escalation for Intermediate- and High-Risk Localized Prostate Cancer: Results of EORTC Trial 22991.

L. Collette, M. Bolla, J. Bosset, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant Folfox4 with or without Cetuximab (CTX) in Patients (PTS) with Resected Stage III Colon Cancer (CC): Dfs and OS Results and Subgroup Analyses of the PETACC8 Intergroup Phase III Trial

L. Collette, P. Laurent-Puig, C. Lepage, 2012 .

EORTC Radiation Oncology Group: 50 years of continuous accomplishments

H. Bartelink, J. Horiot, L. Collette, 2012 .

Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: a phase III study of the European organization for research and treatment of cancer genitourinary group.

L. Collette, S. Fosså, N. Aaronson, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Uptake of two 10B‐compounds in liver metastases of colorectal adenocarcinoma for extracorporeal irradiation with boron neutron capture therapy (EORTC Trial 11001)

L. Collette, K. Jöckel, K. Schmid, 2007, International journal of cancer.

A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974).

L. Collette, C. Bokemeyer, M. D. De Santis, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Raltitrexed (Tomudex) versus standard leucovorin-modulated bolus 5-fluorouracil: Results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1).

R. Labianca, L. Collette, A. Carrato, 2008, European journal of cancer.

The addition of a boost dose on the primary tumour bed after lumpectomy in breast conserving treatment for breast cancer. A summary of the results of EORTC 22881-10882 "boost versus no boost" trial.

R. Müller, H. Bartelink, J. Horiot, 2008, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

The influence of the boost in breast-conserving therapy on cosmetic outcome in the EORTC "boost versus no boost" trial. EORTC Radiotherapy and Breast Cancer Cooperative Groups. European Organization for Research and Treatment of Cancer.

H. Bartelink, J. Horiot, J. Jager, 1999, International journal of radiation oncology, biology, physics.

Pooled Analysis of external-beam RADiotherapy parameters in phase II and phase III trials in radiochemotherapy in Anal Cancer (PARADAC).

L. Collette, J. Ajani, K. Haustermans, 2019, European journal of cancer.

Mitomycin C with continuous fluorouracil or with cisplatin in combination with radiotherapy for locally advanced anal cancer (European Organisation for Research and Treatment of Cancer phase II study 22011-40014).

L. Collette, K. Haustermans, J. Bosset, 2009, European journal of cancer.

EORTC-ROG expert opinion: radiotherapy volume and treatment guidelines for neoadjuvant radiation of adenocarcinomas of the gastroesophageal junction and the stomach.

L. Collette, K. Haustermans, A. Kuten, 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Statistical methodology for personalized medicine: New developments at EORTC Headquarters since the turn of the 21st Century

L. Collette, T. Gorlia, S. Litière, 2012 .

N-of-1 trials in oncology.

L. Collette, B. Tombal, 2015, The Lancet. Oncology.

FSH suppression and tumour control in patients with prostate cancer during androgen deprivation with a GnRH agonist or antagonist

L. Collette, E. Crawford, J. Moul, 2018, Scandinavian journal of urology.

Morbidity from pelvic lymphadenectomy in men undergoing radical prostatectomy.

L. Collette, U. Studer, 2006, European urology.

A phase II multicentre study of irinotecan (CPT 11) in combination with cisplatin (CDDP) in metastatic or locally advanced penile carcinoma (EORTC PROTOCOL 30992).

L. Collette, C. Théodore, I. Bodrogi, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Implications of prostate-specific antigen doubling time as indicator of failure after surgery or radiation therapy for prostate cancer.

L. Collette, A. Bossi, M. Maffezzini, 2007, European urology.

Does post-operative radiotherapy (P-RXT) after radical prostatectomy (Px) improve progression-free survival (PFS) in pT3NO prostate cancer (PC)? (EORTC 22911)

L. Collette, P. Rigatti, M. Bolla, 2004 .

Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study.

L. Collette, G. Calais, M. Bolla, 2014, The Lancet. Oncology.

Prostate Cancer: Prognostic factors, markers of outcome and design of clinical trials

L. Collette, 2006 .

Short Androgen Suppression and Radiation Dose Escalation in Prostate Cancer: 12-Year Results of EORTC Trial 22991 in Patients With Localized Intermediate-Risk Disease

L. Collette, P. Maingon, M. Bolla, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prostate-specific antigen (PSA) alone is not an appropriate surrogate marker of long-term therapeutic benefit in prostate cancer trials.

L. Collette, T. Burzykowski, F. Schröder, 2006, European journal of cancer.

Early versus delayed endocrine treatment of pN1-3 M0 prostate cancer without local treatment of the primary tumor: results of European Organisation for the Research and Treatment of Cancer 30846--a phase III study.

L. Collette, S. Fosså, K. Kurth, 2004, The Journal of urology.

The role of meta-analyses in assessing cancer treatments.

L. Collette, R. Sylvester, L. Duchateau, 2000, European journal of cancer.

External validity of a prediction rule for residual mass histology in testicular cancer: an evaluation for good prognosis patients

J. Habbema, L. Collette, E. Steyerberg, 2003, British Journal of Cancer.

The influence of the boost technique on local control in breast conserving treatment in the EORTC 'boost versus no boost' randomised trial.

H. Bartelink, J. Horiot, J. Jager, 2004, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Quality assurance in the EORTC phase III randomised 'boost vs. no boost' trial for breast conserving therapy: comparison of the results of two individual case reviews performed early and late during the accrual period.

H. Bartelink, J. Horiot, M. Piérart, 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Palliative-care trials: how best to publish findings?

L. Collette, A. Bottomley, M. Mauer, 2008, The Lancet. Oncology.

Metastasis free survival (MFS) is a surrogate for overall survival (OS) in localized prostate cancer (CaP)

P. Kantoff, L. Collette, M. Sydes, 2016 .

The role and impact of pathology review on stage and grade assessment of stages Ta and T1 bladder tumors: a combined analysis of 5 European Organization for Research and Treatment of Cancer Trials.

R Sylvester, L Collette, L. Collette, 2000, The Journal of urology.

Disease-free survival (DFS) as a surrogate for overall survival (OS) in localized prostate cancer (CaP)

P. Kantoff, L. Collette, M. Sydes, 2016 .

Metastatic prostate cancer treated by flutamide versus cyproterone acetate. Final analysis of the "European Organization for Research and Treatment of Cancer" (EORTC) Protocol 30892.

L. Collette, T. D. de Reijke, K. Kurth, 2004, European urology.

Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in CANcer trials).

Karin Haustermans, Simone Mathoulin-Pélissier, Julien Taieb, 2014, European journal of cancer.

Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals.

Tomasz Burzykowski, Laurence Collette, L. Collette, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

EORTC 22972-26991/MRC BR10 trial: fractionated stereotactic boost following conventional radiotherapy of high grade gliomas. Clinical and quality-assurance results of the stereotactic boost arm.

L. Collette, C. Dehing-Oberije, J. Bernier, 2008, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Nomogram to predict ipsilateral breast relapse based on pathology review from the EORTC 22881-10882 boost versus no boost trial.

H. Bartelink, L. Collette, E. van Werkhoven, 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Impact of the boost dose on local control and survival in patients with early stage breast cancer after a microscopically incomplete lumpectomy : 10 years results of the randomised EORTC boost trial 22881/10882.

H. Bartelink, J. Horiot, M. Piérart, 2006 .

Association of Increased Prostate-Specific Antigen Levels After Treatment and Mortality in Men With Locally Advanced vs Localized Prostate Cancer

A. D'Amico, Ming-Hui Chen, L. Collette, 2021, JAMA network open.

From a Comic Opera to Surcare an Open Letter to Whom Clinical Research in Surgery Is a Concern: Announcing the Launch of SURCARE.

L. Collette, D. Lacombe, G. Poston, 2016, Annals of Surgery.

Does local treatment of the prostate in advanced and/or lymph node metastatic disease improve efficacy of androgen-deprivation therapy? A systematic review.

L. Collette, P. Verhagen, C. Bangma, 2010, European urology.

Can radical prostatectomy benefit patients despite the presence of regional metastases?

L. Collette, R. Sylvester, U. Studer, 2010, European urology.

Diagnostic and prognostic factors in patients with prostate cancer: a systematic review protocol

L. Collette, G. Gandaglia, A. Briganti, 2021, BMJ Open.

Intensive induction chemotherapy with C-BOP/BEP for intermediate- and poor-risk metastatic germ cell tumours (EORTC trial 30948)

L Collette, L. Collette, S. Fosså, 2005, British Journal of Cancer.

Comparison of 68Ga-Prostate Specific Membrane Antigen (PSMA) Positron Emission Tomography Computed Tomography (PET-CT) and Whole-Body Magnetic Resonance Imaging (WB-MRI) with Diffusion Sequences (DWI) in the Staging of Advanced Prostate Cancer

L. Collette, B. Tombal, F. Lecouvet, 2021, Cancers.

WHAT HAS BEEN LEARNED FROM META‐ANALYSES OF NEOADJUVANT AND ADJUVANT CHEMOTHERAPY IN BLADDER CANCER?

L. Collette, C. Sternberg, 2007, BJU international.

Local Failure and Survival After Definitive Radiotherapy for Aggressive Prostate Cancer: An Individual Patient-level Meta-analysis of Six Randomized Trials.

A. Kishan, L. Collette, P. Boutros, 2019, European Urology.

Diagnostic and prognostic factors in patients with prostate cancer: a systematic review

L. Collette, M. Roobol, G. Gandaglia, 2022, BMJ Open.

Moving forward toward standardizing analysis of quality of life data in randomized cancer clinical trials

L. Collette, M. Piccart, M. Taphoorn, 2018, Clinical trials.

Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911.

T. H. van der Kwast, L. Collette, M. Bolla, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

MRI versus 18F-FDG-PET/CT for detecting bone marrow involvement in multiple myeloma: diagnostic performance and clinical relevance

L. Collette, D. Boyadzhiev, N. Michoux, 2019, European Radiology.

Late toxicity following conventional radiotherapy for prostate cancer: analysis of the EORTC trial 22863.

M. Piérart, L. Collette, L. Blank, 2004, European journal of cancer.

Impact of pathological characteristics on local relapse after breast-conserving therapy: a subgroup analysis of the EORTC boost versus no boost trial.

A. Hart, J. Peterse, H. Bartelink, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of the boost dose of 10 Gy versus 26 Gy in patients with early stage breast cancer after a microscopically incomplete lumpectomy: 10-year results of the randomised EORTC boost trial.

E. van Limbergen, H. Bartelink, J. Horiot, 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Responding to the challenges of international collaborations between the east and the west – report of the first JCOG–EORTC symposium and a perspective from young JCOG and EORTC investigators

L. Collette, D. Lacombe, P. Starlinger, 2018, Japanese journal of clinical oncology.

Collaboration between EORTC and JCOG—how to accelerate global clinical research partnership

L. Collette, D. Lacombe, M. Shiozawa, 2016, Japanese journal of clinical oncology.

EORTC1527/JCOG1609INT: Diffusion-weighted MRI (DW-MRI) assessment of liver metastasis to improve surgical planning (DREAM).

L. Collette, M. Ducreux, S. Tejpar, 2017 .

Selection of appropriate end-points (pCR vs 2yDFS) for tailoring treatments with prediction models in locally advanced rectal cancer.

P. Lambin, L. Collette, J. Bosset, 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

International experts’ panel for the development of guidelines for the definition of time to event endpoints in clinical trials (DATECAN project): Results for pancreatic cancer.

R. Labianca, L. Collette, D. Aust, 2012 .

A unique research infrastructure from the European Organisation for Research and Treatment of Cancer (EORTC) to optimize long-term follow up of patients-the YOU (Your Outcome Update) protocol: Rationale, scope, design and research opportunities

L. Collette, D. Lacombe, F. Meunier, 2018 .

Adjuvant radiotherapy after surgery for pathologically advanced prostate cancer.

T. H. van der Kwast, L. Collette, M. Bolla, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II EORTC trial with 5-fluorouracil, cisplatin and interferon-alpha as second-line treatment of advanced transitional cell cancer of the urothelial tract.

L. Collette, C. Sternberg, P. D. De Mulder, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

A new measure of treatment effect in clinical trials involving competing risks based on generalized pairwise comparisons

L. Collette, M. Buyse, C. Legrand, 2020, Biometrical journal. Biometrische Zeitschrift.

Adaptive designs at European Organisation for Research and Treatment of Cancer (EORTC) with a focus on adaptive sample size re-estimation based on interim-effect size.

M Mauer, L Collette, J Bogaerts, 2012, European journal of cancer.

EORTC trial 11001: distribution of two 10B‐compounds in patients with squamous cell carcinoma of head and neck, a translational research/phase 1 trial

L. Collette, K. Jöckel, K. Schmid, 2009, Journal of cellular and molecular medicine.

Early clinical trial concept for boron neutron capture therapy: a critical assessment of the EORTC trial 11001.

L. Collette, A. Wittig, W. Sauerwein, 2009, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

Redefining the IGCCCG classification in advanced non-seminoma

L. Collette, R. Huddart, D. Feldman, 2019, Annals of Oncology.

Importance of bleomycin in combination chemotherapy for good prognosis testicular non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group

L. Collette, R. Sylvester, S. Kaye, 1997 .

7007 Three years of adjuvant androgen deprivation with goserelin in patients with locally advanced prostate cancer treated with radiotherapy: Results at 10 years of EORTC trial 22863

M. Piérart, L. Collette, R. Mirimanoff, 2009 .

OC-0522: 3D-CRT/IMRT with/without short term androgen deprivation in localized T1b-cT2aN0M0 prostate cancer (EORTC 22991)

L. Collette, M. Bolla, A.C.M. van den Bergh, 2014 .

Development of clinical trial protocols involving advanced radiation therapy techniques: the European Organisation for Research and Treatment of Cancer Radiation Oncology Group approach.

L. Collette, D. Lacombe, V. Grégoire, 2012, European journal of cancer.

Using both clinical research and population-based cancer registry in long-term research- a case study using EORTC trials and the Dutch national cancer registry (IKNL)

L. Collette, O. Visser, A. Neven, 2020, Journal of Cancer Policy.

The impact of a boost dose on the local recurrence rate in high risk patients after breast conserving therapy – results from the EORTC boost-no boost trial

H. Bartelink, J. Jager, L. Collette, 2008 .

Collaboration between EORTC and JCOG-how to accelerate global clinical research partnership.

L. Collette, D. Lacombe, M. Shiozawa, 2016, Japanese journal of clinical oncology.

6N Irradiation of the internal mammary and medial supraclavicular lymph node chain in stage I to III breast cancer: state of the day of EORTC phase III trial 22922/10925 with 4004 patients

H. Bartelink, L. Collette, V. Budach, 2010 .

10-year Results of Adjuvant Radiotherapy after Radical Prostatectomy in pT3N0 Prostate Cancer (EORTC 22911)

L. Collette, M. Bolla, B. Tombal, 2010 .

804 IMMEDIATE OR DEFERRED ANDROGEN DEPRIVATION FOR PATIENTS WITH PROSTATE CANCER AND NO LOCAL TREATMENT OF THE PROSTATE: LONG TERM RESULTS OF EORTC 30891

L. Collette, U. Studer, S. Madersbacher, 2011 .

218 ADJUVANT RADIATION FOR PATHOLOGICALLY ADVANCED PROSTATE CANCER: A HEAD TO HEAD COMPARISON OF SWOG AND EORTC TRIALS

L. Collette, M. Bolla, H. Poppel, 2011 .

Prostate cancer: pT3N0M0 prostate cancer: a plea for adjuvant radiation

Michel Bolla, Laurence Collette, L. Collette, 2009, Nature Reviews Urology.

Surgical Safety of Cytoreductive Nephrectomy Following Sunitinib: Results from the Multicentre, Randomised Controlled Trial of Immediate Versus Deferred Nephrectomy (SURTIME).

L. Collette, C. Blank, H. V. van Melick, 2019, European urology.

Cytoreductive nephrectomy and exposure to sunitinib - a post-hoc analysis of the SURTIME trial.

L. Collette, B. Tombal, C. Blank, 2021, BJU international.

Acute and late toxicity of post-operative external irradiation in pT3N0 prostate cancer patients treated within EORTC trial 22911

M. Piérart, L. Collette, P. Rigatti, 2002 .

2001 Acute toxicity of curative radiotherapy for intermediate risk localized prostate cancer in the EORTC trial 22991

L. Collette, M. Bolla, S. Sundar, 2009 .

Long term results of immediate adjuvant hormonal therapy with goserelin in patients with locally advanced prostate cancer treated with radiotherapy — A phase III EORTC study

M. Piérart, L. Collette, R. Mirimanoff, 1999 .

5 Long term results of immediate adjuvant hormonal therapy with goserelin in patients with locally advanced prostate cancer treated with radiotherapy. A phase III EORTC study

M. Piérart, L. Collette, R. Mirimanoff, 1999 .

What can be concluded from the ERSPC and PLCO trial data?

L. Collette, U. Studer, 2010, Urologic oncology.

Prostate cancer: To screen or not to screen?

L. Collette, U. Studer, 2009, Nature Reviews Urology.

How to Interpret Results

L. Collette, 2012 .

The influence of the boost technique on local control in breast conserving treatment in the EORTC ‘boost versus no boost’ trial

H. Bartelink, J. Horiot, J. Jager, 2004 .

Prognostic factors in advanced seminoma: An analysis from the IGCCCG Update Consortium.

L. Collette, R. Huddart, D. Feldman, 2020 .

Update of the international prognostic classification for first line metastatic germ-cell cancers. An international initiative

L. Collette, 2017 .

Bleomycin in Combination Chemotherapy of Testicular or Extragonadal Germ Cell Tumours: a Review of Published Trials

L. Collette, J. Shamash, M. Mason, 2002 .

19 WHICH SUBGROUPS OF PATIENTS WITH NEWLY DIAGNOSED TO-4 NO-2 MO PROSTATE CANCER NOT SUITABLE FOR LOCAL TREATMENT WITH CURATIVE INTENT (EORTC 30891) ARE AT RISK TO DIE FROM PROSTATE CANCER AND BENEFIT FROM IMMEDIATE ANDROGEN DEPRIVATION?

L. Collette, T. Reijke, U. Studer, 2007 .

Ten Year Results of Long Term Adjuvant Androgen Deprivation with Goserelin in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy: A Phase III EORTC Study

M. Piérart, L. Collette, R. Mirimanoff, 2008 .

Prophylactic Cranial Irradiation (PCI) in Extensive Stage Small Cell Lung Cancer (ES-SCLC) (EORTC 22993-08993)

L. Collette, P. Postmus, M. Mauer, 2007 .

A randomized trial of prophylactic cranial irradiation (PCI) versus no PCI in extensive disease small cell lung cancer after a response to chemotherapy (EORTC 08993–22993)

L. Collette, C. Faivre-Finn, S. Senan, 2007 .

L. Collette, E. Coche, J. Machiels, 2012, European urology.

L. Collette, I. Skoneczna, H. Schmoll, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Laryngeal preservation with induction chemotherapy for hypopharyngeal squamous cell carcinoma: 10-year results of EORTC trial 24891.

L. Collette, J. Langendijk, G. Andry, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer.

L. Collette, D. Lacombe, C. Sternberg, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Duration of androgen suppression in the treatment of prostate cancer.

M. Piérart, L. Collette, T. D. de Reijke, 2009, The New England journal of medicine.

Why phase III trials of maximal androgen blockade versus castration in M1 prostate cancer rarely show statistically significant differences *

L. Collette, R. Sylvester, U. Studer, 2001, The Prostate.

Does local treatment of the prostate in advanced and/or lymph node metastatic disease improve efficacy of androgen-deprivation therapy? A systematic review.

L. Collette, P. Verhagen, C. Bangma, 2010, European urology.

Chemotherapy with Preoperative Radiotherapy in Rectal Cancer

L. Collette, G. Calais, J. Bosset, 2007 .

Sample size computation in phase II designs combining the A’Hern design and the Sargent and Goldberg design

Laurence Collette, Anouk Neven, Murielle Mauer, 2020, Journal of biopharmaceutical statistics.

Internal Mammary and Medial Supraclavicular Irradiation in Breast Cancer.

E. van Limbergen, I. Barillot, S. Marnitz, 2015, The New England journal of medicine.

Toxicity at three years with and without irradiation of the internal mammary and medial supraclavicular lymph node chain in stage I to III breast cancer (EORTC trial 22922/10925)

H. Bartelink, M. Piérart, L. Collette, 2010, Acta oncologica.

University of Birmingham Moving forward toward standardizing analysis of quality of life data in randomized cancer clinical trials

L. Collette, M. Piccart, M. Taphoorn, 2018 .

Postoperative radiotherapy for high-risk prostate cancer – Authors' reply

L. Collette, M. Bolla, 2013, The Lancet.

Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data

L. Collette, M. Parmar, T. Eisen, 2013, The Lancet. Oncology.

Profile of European radiotherapy departments contributing to the EORTC Radiation Oncology Group (ROG) in the 21st century.

L. Collette, G. Tienhoven, A. Monti, 2008, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

A phase II multicentre study of irinotecan (CPT 11) in combination with cisplatin (CDDP) in metastatic or locally advanced penile carcinoma (EORTC PROTOCOL 30992).

L. Collette, C. Théodore, I. Bodrogi, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Dummy run and conformity indices in the ongoing EORTC low-grade glioma trial 22033-26033: First evaluation of quality of radiotherapy planning.

Damien C Weber, Akos Gulyban, Erik Roelofs, 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.